Log in to your Inderes Free account to see all free content on this page.
Diamyd Medical
17.44 SEK -3.22%1 investor is following this company
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DMYD B
Daily low / high price
17.38 / 18.1
SEK
Market cap
1.74B SEK
Turnover
4.92M SEK
Volume
278K
Latest videos
Financial calendar
Annual report
09.10.2024
General meeting
05.12.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 12.9 % | 10.3 % |
Bertil Lindkvist | 9.2 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Diamyd Medical AB: Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes
Diamyd Medical AB: Quarterly Report III 23/24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio